Valuation: Quest PharmaTech Inc.

Market Cap 3.38M 2.41M 2.16M 2M 1.81M 230M 3.42M 23.9M 9.52M 120M 9.04M 8.85M 381M P/E 2025
-3.29x
P/E 2026 1.18x
Enterprise Value 4.37M 3.11M 2.79M 2.58M 2.34M 296M 4.42M 30.87M 12.29M 155M 11.68M 11.43M 492M EV / Sales 2025
-
EV / Sales 2026 -
Free-Float
83.12%
Yield 2025 *
-
Yield 2026 -
Current month-20.00%
6 months-33.33%
Current year-42.86%
1 month 0.02
Extreme 0.02
0.02
Current year 0.02
Extreme 0.02
0.04
1 year 0.02
Extreme 0.02
0.05
3 years 0.02
Extreme 0.015
0.07
5 years 0.02
Extreme 0.015
0.16
10 years 0.02
Extreme 0.015
0.32
Manager TitleAgeSince
Chief Executive Officer - 16/06/2004
Director of Finance/CFO - 31/12/2004
Director TitleAgeSince
Director/Board Member - 16/06/2004
Chairman - 04/07/2021
Director/Board Member - 04/07/2021
Date Insider Type Main position Quantity % Market Cap. Importance
12/12/25 OtherCompany 0 0% -
21/10/25 Other

Chief Executive Officer

1,000,000 0.5913%
21/10/25 Other

Chief Executive Officer

300,000 0.1774%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%-42.86%-66.67% 2.41M
+0.34%-3.03%+37.45%+61.06% 64.14B
+0.98%+2.68%+12.25%+83.90% 55.53B
+1.75%+2.01%+13.30%+105.71% 53.03B
-1.57%-0.65%+26.93%+56.07% 45.99B
-0.79%-2.85%+17.95%+99.00% 42.45B
+0.34%+1.04%+226.85%+933.46% 40.45B
-0.26%-4.20%+10.86%+45.18% 32.25B
-2.07%+42.73%+103.77%+90.26% 34.47B
-2.72%-8.79%+22.58%-5.63% 24.23B
Average -0.43%+3.44%+42.91%+140.24% 39.25B
Weighted average by Cap. -0.21%+3.13%+49.52%+160.88%

Financials

2025 2026
Net sales - -
Net income -1.8M -1.28M -1.15M -1.06M -964K -122M -1.82M -12.73M -5.07M -63.95M -4.82M -4.71M -203M 5M 3.56M 3.2M 2.95M 2.68M 339M 5.06M 35.32M 14.07M 177M 13.36M 13.08M 563M
Net Debt 795K 566K 508K 470K 425K 53.94M 805K 5.62M 2.24M 28.23M 2.13M 2.08M 89.61M 986K 702K 630K 583K 528K 66.88M 998K 6.96M 2.77M 35M 2.64M 2.58M 111M
Projected Income Statement - Annual - Quest PharmaTech Inc.
Logo Quest PharmaTech Inc.
Quest PharmaTech Inc. is a Canada-based biopharmaceutical company. The Company is developing products to improve the quality of life. The Company is also developing a proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer. The Company has a 42.5% ownership interest in OncoQuest Inc. (OncoQuest), a Canadian biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest’s technology platform included a panel of tumor antigen-specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. The Company also has a 23% ownership interest in OncoVent Co., Ltd. (OncoVent), which is developing antibody-based immunotherapeutic products for cancer for the Greater China territory.
Employees
-
Date Price Change Volume
29/10/26 CA$0.0200 0.00% 2,000